Two newly approved medications expand options beyond lifestyle modifications for metabolic dysfunction-associated steatotic ...

As such, at ESMO 2025, the investigators analyzed patients with or without baseline bone metastases treated with lenvatinib + pembrolizumab versus sunitinib in the CLEAR study with ∼4 years follow-up ...

Keytruda plus Lenvima demonstrates durable 5-year survival benefit versus chemotherapy for patients with advanced endometrial carcinoma following one prior platinum-based regimen ...